Protease Inhibitors Market Size, Share and Global Trend, By Disease Indication (HIV/AIDS,Hepatitis C,Alpha-1 Antitrypsin Deficiency,Hereditary Angioedema (HAE),Others), By Distribution Channel (Hospitals pharmacies,Retail pharmacies,Online pharmacies), and Regional Forecast, 2024-2032
KEY MARKET INSIGHTS
Protease inhibitors have extensive applications in disease prevention, there are many pharmaceutical & biotechnological companies and research institutions those are focusing on discovery of protease inhibitors as new therapeutic drugs. For instance, LEADING BIOSCIENCES INC, a pharmaceutical company has initiated phase 2 clinical trials for LB1148, a serine protease inhibitor to evaluate its efficacy in improving GI function in a patient undergoing major cardiovascular surgery. With the gained popularity and demand for use of protease inhibitors in HIV and hepatitis, there has been a significant rise in demand of protease inhibitors globally.
The growth in global protease inhibitors market is anticipated to be driven by the increased research for clinical application of protease inhibitors combined with the rise in demand of protease inhibitors in various fields. Moreover, the potential pipeline protease inhibitor products especially for HIV, are anticipated to fuel the global protease inhibitors market during the forecast period.
To gain extensive insights into the market, Request for Customization
However, the side effects and unbearable toxicity associated with the protease inhibitors are the factors that are likely to hamper the growth in global protease inhibitors market.
Key Players Covered
Some of the major companies that are present in the global protease inhibitors market are Merck KGaA, Boehringer Ingelheim International GmbH, AbbVie Inc., Bristol-Myers Squibb Company, Janssen Pharmaceutical Companies, GlaxoSmithKline plc, Vertex Pharmaceuticals Incorporated and other players.
Segmentation
Segmentation | Details |
By Disease Indication | · HIV/AIDS · Hepatitis C · Alpha-1 Antitrypsin Deficiency · Hereditary Angioedema (HAE) · Others |
By Distribution Channel | · Hospitals pharmacies · Retail pharmacies · Online pharmacies |
By Geography | · North America (USA and Canada) · Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe) · Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific) · Latin America (Brazil, Mexico and Rest of Latin America) · Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa) |
As of 2018, HIV/AIDS disease indication is anticipated to account for the highest share in the global protease inhibitor market owing to increasing prevalence of the disease.
Key Insights
- Pipeline analysis
- Prevalence of HIV/AIDS
- Regulatory scenario for key countries
- Key mergers and acquisitions
Regional Analysis
The global protease inhibitors market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America is expected to witness the highest growth in the protease inhibitors market during the forecast period owing to the increased clinical trials for HIV protease inhibitors and increased healthcare expenditure. According to the Centers for Disease Control and Prevention, approximately 38,500 new cases of HIV infection were added in 2015 in the U.S., which is likely to augment the growth in protease inhibitors market in North America. The protease inhibitors market is estimated to flourish in the Asia Pacific and Europe in the projected duration due to the advancements in health infrastructure and raising awareness about anti-retroviral therapy for HIV.
Key Industry Developments
- In February 2018, AbbVie Inc. received the positive recommendation for MAVIRET by CADTH Canadian Drug Expert Committee (CDEC). MAVIRET is a therapy for chronic hepatitis C virus (HCV) infection containing NS3/4A protease inhibitor.
- In January 2016, Merck & Co., Inc. received FDA approval for ZEPATIER, a drug manufactured using NS3/4A protease inhibitor for the treatment of chronic hepatitis C virus (HCV)
- In July 2018, Janssen Pharmaceutical Companies received U.S Food and Drug Administration (FDA)approval for the SYMTUZA, a protease inhibitor class of drug indicated for the treatment of HIV-1 Infection.
- Ongoing
- 2023
- 2019-2022
-
Get in Touch with Us
-
US +1 833 909 2966 ( Toll Free )
-
